what is the name of the compound p4010
Phosphorus pentoxide
title: Gepirone text: However, in March 2016, the FDA reversed its decision and gave gepirone ER a positive review, clearing the way for the drug to finally gain market approval in the U.S. As of September 2017, it is still in preregistration. During its development it has been called BMY 13805, MJ 13805, Org 33062, and TGFK07AD and it has had two proposed trade names: Travivo and Variza. Gepirone Gepirone is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be title: CAR-302,196 text: CAR-302,196 CAR-302,196 (also known as PCMG or just by its code number 302196) is a moderately potent and relatively short lasting anticholinergic deliriant drug, related to the chemical warfare agent 3-Quinuclidinyl benzilate (QNB). It was developed under contract to Edgewood Arsenal during the 1960s as part of the US military chemical weapons program, during research to improve upon the properties of earlier agents such as QNB. CAR-302,196 was found to be only around 1/4 the potency of QNB, but its onset of action was much faster at only a few minutes, and the duration far shorter at only 2-3 hours. title: Phencyclidine text: on the street during the 1970s and 1980s, mainly in the United States. The best known of these are rolicyclidine (PCPy or 1-(1-phenylcyclohexyl)pyrrolidine); eticyclidine (PCE or "N"-ethyl-1-phenylcyclohexylamine); and tenocyclidine (TCP or 1-(1-(2-thienyl)cyclohexyl)piperidine). Only of a few of these compounds were widely used. The generalized structural motif required for PCP-like activity is derived from structure-activity relationship studies of PCP derivatives, and summarized in the illustration (right). All of these derivatives are likely to share some of their psychoactive effects with PCP itself, although a range of potencies and varying mixtures of anesthetic, dissociative and stimulant effects are known, depending on the title: Nariman Mehta text: Inc., now GlaxoSmithKline, where he worked on potential neuropsychopharmacological drugs and designed, synthesized, and patented (in 1969) the compound Bupropion (BW 323U66) that was approved for use as an antidepressant in 1985 and sold under the trade name Wellbutrin. Another application of the drug was as a smoking cessation aid. Nariman Mehta Nariman Bomanshaw Mehta (April 8, 1920 – August 22, 2014) was an Indian-born American organic chemist and pharmacologist who designed, synthesized, and patented the organic compound Bupropion, marketed under the name Wellbutrin as an antidepressant and smoking cessation aid. Mehta was born in Bombay, India into a Parsi title: Tenofovir disoproxil text: Atripla (tenofovir disoproxil/emtricitabine/efavirenz), Complera (tenofovir disoproxil/emtricitabine/rilpivirine), Stribild (tenofovir disoproxil/emtricitabine/elvitegravir/cobicistat), and Truvada (tenofovir disoproxil/emtricitabine). Gilead has created a second pro-drug form of the active drug, tenofovir diphosphate, called tenofovir alafenamide. It differs from tenofovir disoproxil due to its activation in the lymphoid cells. This allows the active metabolites to accumulate in those cells, leading to lower systemic exposure and potential toxicities. Tenofovir has a melting point of . Tenofovir disoproxil fumarate is a white to off-white crystalline powder that is soluble in methanol, slightly soluble in water (13.4 mg/ml), and very slightly soluble in dichloromethane. Tenofovir may be measured in plasma